Savara (SVRA) EBITDA (2010 - 2026)
Savara (SVRA) posted quarterly EBITDA of -$39.0 million for Q1 2026, down 37.12% year-over-year from -$62.0 million in Q1 2025, and down 16.67% quarter-over-quarter from -$33.4 million in Q4 2025.
Savara (SVRA) EBITDA (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported EBITDA for 17 consecutive years, with -$39.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 37.12% year-over-year to -$39.0 million; the TTM figure through Mar 2026 stood at -$134.1 million (down 22.86% YoY), while the FY2025 annual figure was -$123.5 million, down 19.72% from the prior year.
- EBITDA eased to -$39.0 million in Q1 2026 per SVRA's latest filing, from -$33.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$8.0 million in Q1 2022 and bottomed at -$39.0 million in Q1 2026.
- Historically, EBITDA has averaged -$21.4 million across 5 years, with a median of -$22.5 million in 2024.
- Annual changes were most pronounced in 2022 — EBITDA gained 22.74% — and 2024, when it plunged 89.76%.
- Savara's EBITDA stood at -$10.9 million in 2022, then sank by 62.11% to -$17.6 million in 2023, then plunged by 76.82% to -$31.2 million in 2024, then dropped by 7.2% to -$33.4 million in 2025, then dropped by 16.67% to -$39.0 million in 2026.
- Business Quant data shows SVRA's EBITDA at -$39.0 million in Q1 2026, -$33.4 million in Q4 2025, and -$30.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -40.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.97 Mn |
| Mar 31, 2026 | -38.99 Mn |
| Dec 31, 2025 | -33.42 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -28.44 Mn |
| Dec 31, 2024 | -31.17 Mn |
| Sep 30, 2024 | -26.36 Mn |
| Jun 30, 2024 | -23.19 Mn |
| Mar 31, 2024 | -22.48 Mn |
| Dec 31, 2023 | -17.63 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -12.22 Mn |
| Mar 31, 2023 | -12.11 Mn |
| Dec 31, 2022 | -10.88 Mn |
| Sep 30, 2022 | -10.54 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | -8.05 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -9.97 Mn |